All Clinical Trials

A listing of 23116 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Offer

Lose 20% of Body Weight With GLP-1's

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).

Get $50 off your first order using promo code: policy-lab-50

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Buy Retatrutide Online Through Celia

Recruiting

Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.

Conditions:

Healthy

Learn More

Featured Trial

COVID-19 Vaccine Clinical Trial (Compensation Provided)

Recruiting

Healthy adults ages 50-64 may qualify. You may be eligible if you haven’t received a COVID-19 vaccine and haven’t had COVID-19 in the last 90 days.

Qualified participants may receive compensation for time and travel.

Conditions:

Healthy

Vaccine

COVID19

COVID-19

COVID-19 Vaccine

Learn More

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

NCT07105228

Recruiting

This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice. The main objective is to describe demographic and clinical characteristics of patients receiving aflibercept 2mg injections, to estimate the incidence of RV and RV plus Intraocular Inflammation (IOI) following aflibercept 2mg injections and to describe characteristics of RV cases. Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Regeneron Research Site, Tarrytown, New York

Conditions: Retinal Vasculitis

Learn More ›

Visual Plasticity Following Brain Lesions

NCT07105358

Recruiting

The VIBRANT (Vision Improvement through Behavioral Rehabilitation And Neuroplasticity Training) study is a prospective, double-blind, crossover design (within-subject) in participants with homonymous hemianopia-a type of visual field loss resulting from damage to the post-chiasmatic visual pathways. It aims to investigate whether transcranial random noise stimulation (tRNS) combined with perceptual learning-based training has potential for improving visual impairments.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Georgetown University Medical Center, Washington, District of Columbia

Conditions: Visual Field Defect, Stroke, Hemianopia, Quadrantanopia, Cortical Blindness, Brain Tumor, Traumatic Brain Injury, Visual Field Defect, Peripheral

Learn More ›

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07105488

Recruiting

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

07/29/2025

Locations: Antelope Valley Clinical Trials, Lancaster, California +6 locations

Conditions: Atopic Dermatitis (AD)

Learn More ›

Impact of Prebiotic Sodas on Satiety and Metabolic Responses in Healthy Men

NCT07105826

Recruiting

The study aims to study healthy men aged 18-40 to explore how different beverages affect hunger, blood sugar, insulin, and a hormone called GLP-1, which helps regulate appetite and blood sugar. The tested beverages include two prebiotic sodas (Olipop and Poppi), Diet Coke, and Coca-Cola Classic. What's the study about? It aims to understand how these drinks influence how full participants feel and how the body handles sugar and hormones compared to each other. This could help us learn more about how prebiotic drinks, which may support gut health, compare to regular sugary or diet sodas. What will participants do? Participants will visit our lab at TCU (Rickel Building, rooms 256/259) four times over four weeks, with each visit lasting about 2-2.5 hours. Participants will need to fast for 8-12 hours before each visit. Here's what happens: * First visit involves participants' consent, measurement of height and weight, and performing a finger-stick test to check blood sugar and HbA1C. Participants will also fill out questionnaires about health, diet, and beverage preferences. * Visits 2-4: In visit 2, a DEXA scan will be performed to assess body composition. In visits 2-4, participants will drink one of the four beverages (in a random order, served in an unlabeled black container to prevent drink identification). Other variables measured at these time points include blood pressure, fasting glucose, insulin, and GLP-1. Participants will also complete questionnaires about hunger and how the drink tastes. Each visit is spaced out by a week, and the total time commitment is about 10.5 hours. The study is expected to complete participant recruitment by December 10, 2025. Who can join? Ten healthy men aged 18-40 who don't have diabetes, heart disease, kidney or liver issues, or other specific health conditions. Participants shouldn't smoke, vape, or have certain dietary habits like intermittent fasting. Participants will be screened to confirm eligibility. What are the risks? The risks are low but include discomfort from blood draws or the IV catheter, a small chance of infection, and minimal radiation exposure from the DEXA scan (similar to everyday background radiation). There's also a small risk of a data breach, but participant information will be secured with password-protected systems and use ID numbers instead of names. What do participants get? Participants will receive a DEXA scan, baseline blood sugar, and HbA1C tests. If participants have abnormal results (like high blood sugar), doctor visits would be recommended. There are no direct benefits to participants, but participation could help develop better dietary recommendations in the future. How is privacy protected? Data will be stored securely on password-protected computers and in locked lab facilities, following HIPAA rules. Blood samples will be frozen for up to 10 years for possible future research (with participants' consent) and labeled with an ID number, not participants' names. How to join? Participants will be recruited through flyers, emails, social media, and TCU classes. If interested, participants will complete an online screening form or scan a QR code on our flyer. If eligible, participants will be contacted to confirm details and explain the study further. If participants have questions or want to join, contact Dr. Elisa Marroquin at e.marroquin@tcu.edu or Matthew Loritz at m.loritz@tcu.edu. Participation is voluntary, and participants can withdraw at any time, though data will be kept for analysis. Read Less

Gender:

MALE

Ages:

Between 18 years and 40 years

Trial Updated:

07/29/2025

Locations: Texas Christian University, Fort Worth, Texas

Conditions: Olipop, Poppi, Coca Cola - Classic, Diet Coke

Learn More ›

A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease

NCT07106021

Recruiting

This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.

Gender:

ALL

Ages:

Between 45 years and 75 years

Trial Updated:

07/29/2025

Locations: University of Arizona, Tucson, Arizona

Conditions: Idiopathic Parkinson´s Disease, Parkinson's Disease

Learn More ›

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180

Recruiting

The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

Gender:

ALL

Ages:

All

Trial Updated:

07/29/2025

Locations: Not set, Birmingham, Alabama +311 locations

Not set, Birmingham, Alabama

Not set, Anchorage, Alaska

Not set, Chandler, Arizona

Not set, Jonesboro, Arkansas

Not set, Little Rock, Arkansas

Not set, Bakersfield, California

Not set, Chula Vista, California

Not set, La Jolla, California

Not set, Los Angeles, California

Not set, Palm Springs, California

Not set, Rancho Mirage, California

Not set, Redwood City, California

Not set, Salinas, California

Not set, San Diego, California

Not set, Stanford, California

Not set, Torrance, California

Not set, Van Nuys, California

Not set, Ventura, California

Not set, Aurora, Colorado

Not set, Centennial, Colorado

Not set, Colorado Springs, Colorado

Not set, Denver, Colorado

Not set, Lakewood, Colorado

Not set, Hartford, Connecticut

Not set, New Haven, Connecticut

Not set, Washington, District of Columbia

Not set, Bradenton, Florida

Not set, Clearwater, Florida

Not set, Hollywood, Florida

Not set, Jacksonville, Florida

Not set, Panama City, Florida

Not set, Safety Harbor, Florida

Not set, Sarasota, Florida

Not set, Atlanta, Georgia

Not set, Marietta, Georgia

Not set, Evansville, Indiana

Not set, Indianapolis, Indiana

Not set, West Des Moines, Iowa

Not set, Kansas City, Kansas

Not set, Edgewood, Kentucky

Not set, Louisville, Kentucky

Not set, Baton Rouge, Louisiana

Not set, Shreveport, Louisiana

Not set, Baltimore, Maryland

Not set, Bethesda, Maryland

Not set, Clinton, Maryland

Not set, Hyattsville, Maryland

Not set, Salisbury, Maryland

Not set, Silver Spring, Maryland

Not set, Takoma Park, Maryland

Not set, Boston, Massachusetts

Not set, Lansing, Michigan

Not set, Marquette, Michigan

Not set, Ypsilanti, Michigan

Not set, Coon Rapids, Minnesota

Not set, Minneapolis, Minnesota

Not set, Robbinsdale, Minnesota

Not set, Rochester, Minnesota

Not set, Saint Cloud, Minnesota

Not set, Saint Paul, Minnesota

Not set, Hattiesburg, Mississippi

Not set, Columbia, Missouri

Not set, Kansas City, Missouri

Not set, Saint Louis, Missouri

Not set, Omaha, Nebraska

Not set, Marlton, New Jersey

Not set, Morristown, New Jersey

Not set, New Brunswick, New Jersey

Not set, Ocean, New Jersey

Not set, Ridgewood, New Jersey

Not set, Albuquerque, New Mexico

Not set, Huntington, New York

Not set, Manhasset, New York

Not set, New York, New York

Not set, Poughkeepsie, New York

Not set, Utica, New York

Not set, Durham, North Carolina

Not set, Raleigh, North Carolina

Not set, Akron, Ohio

Not set, Cincinnati, Ohio

Not set, Cleveland, Ohio

Not set, Columbus, Ohio

Not set, Toledo, Ohio

Not set, Oklahoma City, Oklahoma

Not set, Portland, Oregon

Not set, Allentown, Pennsylvania

Not set, Bethlehem, Pennsylvania

Not set, Danville, Pennsylvania

Not set, Erie, Pennsylvania

Not set, Lancaster, Pennsylvania

Not set, Philadelphia, Pennsylvania

Not set, Pittsburgh, Pennsylvania

Not set, Wilkes-Barre, Pennsylvania

Not set, Columbia, South Carolina

Not set, Germantown, Tennessee

Not set, Nashville, Tennessee

Not set, Austin, Texas

Not set, Dallas, Texas

Not set, Fort Worth, Texas

Not set, Houston, Texas

Not set, Plano, Texas

Not set, The Woodlands, Texas

Not set, Tyler, Texas

Not set, Burlington, Vermont

Not set, Charlottesville, Virginia

Not set, Olympia, Washington

Not set, Spokane, Washington

Not set, Madison, Wisconsin

Not set, Milwaukee, Wisconsin

Not set, Chermside, Not set

Not set, Douglas, Not set

Not set, Murdoch, Not set

Not set, Southport, Not set

Not set, Graz, Not set

Not set, Innsbruck, Not set

Not set, Linz, Not set

Not set, Wien, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Edegem, Not set

Not set, Leuven, Not set

Not set, Liège, Not set

Not set, Yvoir, Not set

Not set, Calgary, Not set

Not set, Kingston, Not set

Not set, Montreal, Not set

Not set, Québec, Not set

Not set, Beijing, Not set

Not set, Changsha, Not set

Not set, Dalian, Not set

Not set, Fuzhou, Not set

Not set, Guangzhou, Not set

Not set, Hangzhou, Not set

Not set, Harbin, Not set

Not set, Kunming, Not set

Not set, Nanchang, Not set

Not set, Shanghai, Not set

Not set, Shantou, Not set

Not set, Suzhou, Not set

Not set, Taiyuan, Not set

Not set, Tianjin, Not set

Not set, Praha, Not set

Not set, Copenhagen, Not set

Not set, Hellerup, Not set

Not set, Hillerød, Not set

Not set, Odense, Not set

Not set, Århus, Not set

Not set, Helsinki, Not set

Not set, Avignon, Not set

Not set, Bayonne, Not set

Not set, Brest, Not set

Not set, Caen, Not set

Not set, Chambray-lès-Tours, Not set

Not set, Clermont-Ferrand, Not set

Not set, Dijon, Not set

Not set, La Rochelle, Not set

Not set, La Tronche, Not set

Not set, Lille, Not set

Not set, Montpellier, Not set

Not set, Nantes, Not set

Not set, Neuilly-sur-Seine, Not set

Not set, Paris, Not set

Not set, Pessac, Not set

Not set, Pringy, Not set

Not set, Rennes, Not set

Not set, Saint-Priest-en-Jarez, Not set

Not set, Strasbourg, Not set

Not set, Toulouse, Not set

Not set, Vandoeuvre les Nancy, Not set

Not set, Villeurbanne, Not set

Not set, Aachen, Not set

Not set, Bad Oeynhausen, Not set

Not set, Bremen, Not set

Not set, Dresden, Not set

Not set, Düsseldorf, Not set

Not set, Essen, Not set

Not set, Hamburg, Not set

Not set, Hannover, Not set

Not set, Heidelberg, Not set

Not set, Homburg, Not set

Not set, Jena, Not set

Not set, Köln, Not set

Not set, München, Not set

Not set, Münster, Not set

Not set, Tübingen, Not set

Not set, Ulm, Not set

Not set, Villingen-Schwenningen, Not set

Not set, Athens, Not set

Not set, Marousi, Not set

Not set, Thessaloníki, Not set

Not set, Hong Kong, Not set

Not set, Budapest, Not set

Not set, Reykjavik, Not set

Not set, Bangalore, Not set

Not set, Gurgaon, Not set

Not set, New Delhi, Not set

Not set, Ashkelon, Not set

Not set, Be'er Sheva, Not set

Not set, Jerusalem, Not set

Not set, Ramat Gan, Not set

Not set, Ancona, Not set

Not set, Bari, Not set

Not set, Bologna, Not set

Not set, Brescia, Not set

Not set, Castrovillari, Not set

Not set, Cotignola, Not set

Not set, Lecce, Not set

Not set, Milano, Not set

Not set, Monza, Not set

Not set, Pisa, Not set

Not set, Taranto, Not set

Not set, Udine, Not set

Not set, Ageo, Not set

Not set, Gifu, Not set

Not set, Hidaka, Not set

Not set, Hiroshima City, Not set

Not set, Kagoshima, Not set

Not set, Kamakura, Not set

Not set, Kawasaki, Not set

Not set, Kitakyushu, Not set

Not set, Koshigaya, Not set

Not set, Kumamoto, Not set

Not set, Kyoto, Not set

Not set, Mitaka, Not set

Not set, Nagoya, Not set

Not set, Niigata, Not set

Not set, Okayama, Not set

Not set, Sapporo, Not set

Not set, Shinagawa-Ku, Not set

Not set, Shizuoka, Not set

Not set, Suita, Not set

Not set, Tokyo, Not set

Not set, Toyoake, Not set

Not set, Urasoe, Not set

Not set, Yamagata, Not set

Not set, Yokohama, Not set

Not set, Ōsaka-sayama, Not set

Not set, Cheongju-si, Not set

Not set, Daejeon, Not set

Not set, Gyeonggi-do, Not set

Not set, Seoul, Not set

Not set, Suwon-si, Not set

Not set, Hadiya, Not set

Not set, Kuwait, Not set

Not set, Kuala Lumpur, Not set

Not set, Amsterdam, Not set

Not set, Breda, Not set

Not set, Den Haag, Not set

Not set, Eindhoven, Not set

Not set, Enschede, Not set

Not set, Groningen, Not set

Not set, Leiden, Not set

Not set, Maastricht, Not set

Not set, Nieuwegein, Not set

Not set, Rotterdam, Not set

Not set, Christchurch, Not set

Not set, Bergen, Not set

Not set, Oslo, Not set

Not set, Trondheim, Not set

Not set, Poznań, Not set

Not set, Warsaw, Not set

Not set, Zabrze, Not set

Not set, Carnaxide, Not set

Not set, Creixomil, Not set

Not set, Lisboa, Not set

Not set, Porto, Not set

Not set, Santarém, Not set

Not set, Jeddah, Not set

Not set, Riyadh, Not set

Not set, Belgrade, Not set

Not set, Bratislava, Not set

Not set, Košice, Not set

Not set, Ljubljana, Not set

Not set, A Coruña, Not set

Not set, Barcelona, Not set

Not set, Córdoba, Not set

Not set, Girona, Not set

Not set, Granada, Not set

Not set, Madrid, Not set

Not set, Palma De Mallorca, Not set

Not set, Salamanca, Not set

Not set, Santa Cruz De Tenerife, Not set

Not set, Santiago de Compostela, Not set

Not set, Toledo, Not set

Not set, Valencia, Not set

Not set, Valladolid, Not set

Not set, Vitoria-Gasteiz, Not set

Not set, Göteborg, Not set

Not set, Lund, Not set

Not set, Skövde, Not set

Not set, Uppsala, Not set

Not set, Basel, Not set

Not set, Bern, Not set

Not set, Fribourg, Not set

Not set, Geneva, Not set

Not set, Lausanne, Not set

Not set, Lugano, Not set

Not set, Zürich, Not set

Not set, Birmingham, Not set

Not set, Blackpool, Not set

Not set, Bristol, Not set

Not set, Leeds, Not set

Not set, Leicester, Not set

Not set, Liverpool, Not set

Not set, London, Not set

Not set, Manchester, Not set

Not set, Middlesbrough, Not set

Not set, Northampton, Not set

Not set, Nottingham, Not set

Not set, Sheffield, Not set

Not set, Southampton, Not set

Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Learn More ›

Hirschsprung Disease Genetic Study

NCT00478712

Recruiting

Hirschsprung disease is a genetic condition caused by lack of nerve cells in varying lengths of the intestines. This study will investigate the complex genetic basis of the disease, which involves multiple interacting genetic factors.

Gender:

ALL

Ages:

Between 1 week and 100 years

Trial Updated:

07/29/2025

Locations: New York University School of Medicine, New York, New York

Conditions: Hirschsprung Disease

Learn More ›

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT00501826

Recruiting

This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing... Read More

Gender:

ALL

Ages:

All

Trial Updated:

07/29/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma

Learn More ›

Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

NCT00579566

Recruiting

The purpose of this study is to study normal and sarcoma cells. To study these cells we need to have human tissue. You will be having or have already had a procedure to remove tissue. We would like to use some of this tissue. We will use it for laboratory studies on the diagnosis,behavior and treatment of sarcoma. We will perform an extensive analysis of your samples. We will only use extra tissue left over after all needed testing has been done or remove an additional small amount of tissue if... Read More

Gender:

ALL

Ages:

All

Trial Updated:

07/29/2025

Locations: Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up), Basking Ridge, New Jersey +6 locations

Conditions: Sarcoma

Learn More ›

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

NCT01371630

Recruiting

This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy w... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Burkitt-Like Lymphoma With 11q Aberration, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma

Learn More ›

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

NCT01409161

Recruiting

This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotoxins, such as gemtuzumab ozogamicin, may find certain cancer cells and kill the... Read More

Gender:

ALL

Ages:

10 years and above

Trial Updated:

07/29/2025

Locations: M D Anderson Cancer Center, Houston, Texas +4 locations

Conditions: Acute Promyelocytic Leukemia With PML-RARA

Learn More ›

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

NCT02106988

Recruiting

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Lymphoma

Learn More ›